Biofrontera AG (BFRA): $6.09

-0.20 (-3.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Biofrontera AG (BFRA) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Biofrontera AG.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
3 $14.66 $11 $12.89 $6.3 104.6%

Over the past 160 days, BFRA's average upside potential has been 58.21%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2020-11-13 3 14.66 11 12.89 6.91 86.54%
2020-11-10 3 13.70 11 12.57 6.93 81.39%
2020-10-12 3 13.70 11 12.57 7.82 60.74%
2020-08-27 3 13.68 11 12.56 10.35 21.35%
2020-08-19 3 15.00 11 12.71 11.16 13.89%
2020-08-02 3 12.13 8 10.38 5.60 85.36%
2020-07-20 3 12.13 8 10.38 NA NA%
2020-07-01 3 11.33 8 10.11 NA NA%
2020-06-06 3 11.33 8 10.11 NA NA%

BFRA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for BFRA as an investment opportunity.

  • The upside potential (average analyst target price relative to current price) of BFRA is higher than 82.67% of all US stocks.
  • The average analyst price target of BFRA is higher than 24.59% of all US stocks.
  • The number of analysts covering the stock of BFRA is higher than 22.97% of Pharmaceutical Products stocks.
  • BFRA has a less variance in analysts' estimates than 67.05% of Pharmaceutical Products stocks.

Make investment decisions regarding BFRA using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7345 seconds.